Flurbiprofen in the symptomatic management of rheumatoid arthritis: a valuable alternative

Richy, Florent; Rabenda, Véronique; Mawet, Audrey; Reginster, Jean‐Yves

doi:10.1111/j.1742-1241.2007.01452.x

Cited by 35 publications

(29 citation statements)

References 40 publications

(48 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The drug is also used to treat the inflammatory affections of the oral cavity, pharynx and larynx. 3 Here we report a case of hypersensitivity reaction to flurbiprofen oral spray whose outcome was fatal. Reported adverse reactions include contact dermatitis, 5 delayed hypersensitivity 6 and cutaneous vasculitis.…”

Section: What Is Known and Objectivementioning

confidence: 93%

“…8 The global safety of flurbiprofen is comparable with that of ibuprofen and naproxen, and its gastrointestinal tolerance is considered better than that of aspirin and comparable with that of indomethacin, ibuprofen and naproxen. 3 Here we report a case of hypersensitivity reaction to flurbiprofen oral spray whose outcome was fatal.…”

Section: What Is Known and Objectivementioning

confidence: 93%

“…Although it presents a chiral centre, with the S-(+)enantiomer possessing most of the beneficial anti-inflammatory activity, both enantiomers may have analgesic activity and all flurbiprofen preparations to date are marketed as the racemate. 3 Its systemic administration was approved by the United States Food and Drug Administration (US FDA) in 1988 for the treatment of rheumatoid arthritis and osteoarthritis. Absorption of flurbiprofen is rapid and almost complete when administered orally.…”

Section: What Is Known and Objectivementioning

confidence: 99%

“…1 In a number of pharmacological studies, it has been shown to be a potent and effective drug in the treatment of inflammatory conditions, including rheumatoid diseases. 3 Its systemic administration was approved by the United States Food and Drug Administration (US FDA) in 1988 for the treatment of rheumatoid arthritis and osteoarthritis. The drug is also used to treat the inflammatory affections of the oral cavity, pharynx and larynx.…”

Section: What Is Known and Objectivementioning

confidence: 99%

See 3 more Smart Citations

Fatal hypersensitivity reaction to an oral spray of flurbiprofen: a case report

et al. 2013

View full text Add to dashboard Cite

Oral propionic acid derivatives have been associated with a relatively high frequency of allergic reactions. However, allergy to flurbiprofen has rarely been documented. Scientific literature reports two relevant cases of hypersensitivity reaction to flurbiprofen: in one case, a patient presented with a maculopapular rash 48 h after having taken oral flurbiprofen followed by angio-oedema and hypotension. In another case, a single oral dose of flurbiprofen caused itching and swelling around the eyes, redness and increased lacrimation. We describe, for the first time, a fatal case of hypersensitivity reaction to flurbiprofen oral spray. Hypersensitivity reactions to flurbiprofen are infrequent; however, health professionals should be aware of potential adverse reactions, even during topical administration as oral spray.

show abstract

Section: What Is Known and Objectivementioning

confidence: 93%

Section: What Is Known and Objectivementioning

confidence: 93%

Section: What Is Known and Objectivementioning

confidence: 99%

Section: What Is Known and Objectivementioning

confidence: 99%

See 2 more Smart Citations

Fatal hypersensitivity reaction to an oral spray of flurbiprofen: a case report

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Therefore, in the present study, drug-loaded AMP clays have been synthesized and their in vitro, as well as in vivo, characteristics were evaluated. Because flurbiprofen (FB) is one of the widely used nonsteroidal anti-inflammatory drugs (NSAIDs) and is also poorly water-soluble, 15 it was selected as a model drug. Subsequently, drug-loaded organoclays were synthesized at various drug-clay ratios, and their effects on the dissolution and bioavailability of the drug were examined in comparison with the conventional powder formulation.…”

mentioning

confidence: 99%

3-aminopropyl functionalized magnesium phyllosilicate as an organoclay based drug carrier for improving the bioavailability of flurbiprofen

Yang

Choi²,

Shin³

et al. 2013

IJN

View full text Add to dashboard Cite

This study aimed to develop an oral delivery system using clay-based organic–inorganic hybrid materials to improve the bioavailability of the drug, flurbiprofen, which is poorly soluble in water. 3-aminopropyl functionalized magnesium phyllosilicate (AMP clay) was synthesized by a one-pot direct sol-gel method, and then flurbiprofen (FB) was incorporated into AMP clay (FB-AMP) at different drug/clay ratios. The structural characteristics of AMP and FB-AMP formulation were confirmed by X-ray diffraction, Fourier transform infrared spectroscopy, and transmission electron microscopy. Among tested formulations, FB-AMP (3) , dramatically increased the dissolution of FB and achieved rapid and complete drug release within 2 hours. More than 60% of FB was released from FB-AMP (3) after 30 minutes; the drug was completely dissolved in the water within 2 hours. Under the acidic condition (pH 1.2), FB-AMP (3) also increased the dissolution of FB by up to 47.1% within 1 hour, which was three-fold higher than that of untreated FB. Furthermore, following an oral administration of FB-AMP (3) to Sprague-Dawley rats, the peak plasma concentration and area under the plasma concentration-time curve of FB increased two-fold, and the time to reach the peak plasma concentration was shortened compared with that in the untreated FB. This result suggests that the oral drug delivery system using clay-based organic–inorganic hybrid material might be useful to improve the bioavailability of FB.

show abstract

Single dose oral flurbiprofen for acute postoperative pain in adults

Sultan

McQuay

Moore

et al. 2008

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Background Flurbiprofen is a non-selective non-steroidal anti-inflammatory drug (NSAID), related to ibuprofen and naproxen, used to treat acute and chronic painful conditions. There is no systematic review of its use in acute postoperative pain. Objectives To assess e icacy, duration of action, and associated adverse events of single dose oral flurbiprofen in acute postoperative pain in adults. Search methods We searched Cochrane CENTRAL, MEDLINE, EMBASE and the Oxford Pain Relief Database for studies to January 2009. Selection criteria Randomised, double blind, placebo-controlled trials of single dose orally administered flurbiprofen in adults with moderate to severe acute postoperative pain. Data collection and analysis Two review authors independently assessed trial quality and extracted data. Pain relief or pain intensity data were extracted and converted into the dichotomous outcome of number of participants with at least 50% pain relief over 4 to 6 hours, from which relative risk (RR) and number needed to treat to benefit (NNT) were calculated. Numbers of participants using rescue medication over specified time periods, and time to use of rescue medication, were sought as additional measures of e icacy. Information on adverse events and withdrawals were collected. Main results Eleven studies compared flurbiprofen (699 participants) with placebo (362 participants) in studies lasting 6 to 12 hours. Studies were of adequate reporting quality, and most participants had pain following dental extractions. The dose of flurbiprofen used was 25 mg to 100 mg, with most information for 50 mg and 100 mg. The NNT for at least 50% pain relief over 4 to 6 hours for flurbiprofen 50 mg compared with placebo (692 participants) was 2.7 (2.3 to 3.3) and for 100 mg (416 participants) it was 2.5 (2.0 to 3.1). With flurbiprofen 50 mg and 100 mg 65% to 70% of participants experienced at least 50% pain relief, compared with 25% to 30% with placebo. Rescue medication was used by 25% and 16% of participants with flurbiprofen 50 mg and 100 mg over 6 hours, compared with almost 70% with placebo. Adverse events were uncommon, and not significantly di erent from placebo.

show abstract

Flurbiprofen in the symptomatic management of rheumatoid arthritis: a valuable alternative

Abstract: This meta-analysis has shown that flurbiprofen is an interesting alternative to commonly prescribed NSAIDs in the symptomatic management of rheumatoid arthritis, especially given its favourable efficacy/tolerance ratio.

Cited by 35 publications

References 40 publications

Fatal hypersensitivity reaction to an oral spray of flurbiprofen: a case report

Fatal hypersensitivity reaction to an oral spray of flurbiprofen: a case report

3-aminopropyl functionalized magnesium phyllosilicate as an organoclay based drug carrier for improving the bioavailability of flurbiprofen

Single dose oral flurbiprofen for acute postoperative pain in adults

Contact Info

Product

Resources

About